SLC5A2 and diabetic kidney disease: For this reason, patients with DKD should be offered close monitoring and intensive treatment to slower the progression of kidney damage (i.e., strict glycemic control, judicious use of renin-angiotensin-aldosterone blockers, aggressive blood pressure control, and, whenever possible, new drugs that demonstrated to improve renal prognosis, such as SGLT-2 inhibitors).